Since May, Wu Zhou's Aiying medical has begun to produce results, such as testing virus-related equipment.

Originally, it was a special research and development done by the company in order to make a research project for virus purifiers, but I didn't expect the surprise of unexpected derivatives.

"Rapid detection technology based on CRISPR."

The latest research by the team led by Dr. Zhang, a gene editing expert in Aiying Biotech, has found that CRISPR_Cas9 can specifically cut DNA under the guidance of gRNA to achieve gene editing function, so as to achieve rapid genetic detection (Cas13, Cas12a, Csm6), and related articles have been published in Nature and Science.

Compared with traditional molecular diagnostic technologies such as PCR and NGS, CRISPR detection technology has a higher sensitivity, anti-interference, more accurate and more convenient use effect.

While traditional PCR requires dozens of COPE units of the virus to detect, CRISPR detection technology only requires 1-3 COPIES units.

The degree of sensitivity is dozens of times.

And it is also more convenient in the use scenario, no need for large instruments, no laboratory, can be used at home. ”

So.

As a result, after obtaining a large number of clinical trial results, Huaxia gave an accelerated approval process.

If it goes well, at the end of May, or the beginning of June, production should be able to start, and the relevant production lines, Aiying Medical has been working on it, and the existing production lines can be adjusted.

This major news, in mid-May, has been published in relevant authoritative journals, due to the mask temperature raging around the world, has made countless people pay attention to its harm, during this time, related technologies, articles, on SCI, nature such top journals are particularly easy, and the speed of publication is fast.

The emergence of this technology has attracted great attention from the global medical industry, as its data is ahead of other similar detection technologies.

Dr. Zhang became famous for a while.

There is also an endless stream of domestic and foreign media interviews.

"The fact that this technology can be implemented so quickly is not all due to me, but also to the help of my team members and other colleagues in the company, without their help, it is impossible to get results so quickly." Dr. Zhang said with a serious face.

He was telling the truth.

Because the whole research and development process, even in retrospect, is unexpectedly comfortable.

If you encounter a little problem, or the other members of the group suddenly give the right direction.

Or maybe there are other groups in the company who happen to have relevant experts who can help solve the problem.

In addition, the members of the group have super execution.

Unprecedentedly comfortable, I seem to just provide a general direction, ideas, and then the specific landing process, it seems that I don't need to worry too much.

He was very glad at the moment, and he agreed to the invitation of the headhunting company in anger at that time.

But Dr. Zhang told the truth, and the audience who saw the relevant interviews.

But I feel that Dr. Zhang is being modest.

"A humble gentleman."

"This is what we Chinese scientists should really look like."

"Wu Zhou's luck is too good, just entered the medical field, and he won a big bull, the focus is on the results."

"This thing is useful when it comes out of research, but it's all gone in China. There are only one or two that pop up once in a while. ”

"Are you in the ravine, take a look at the international news, there are millions of new additions abroad every day, and I don't know how many people there are."

"Hehe, so what, foreign technology is much more advanced than ours in China."

At the same time, many medical institutions at home and abroad who have noticed this technology are also following up to verify the feasibility of this technical route.

After all, the current global nucleic acid program is very uncomfortable, because the number of viruses required is much higher, so you have to poke your nose and eyes fiercely, which makes many people feel disgusted and even resistant.

But if this hypersensitivity technology is used, then the nucleic acid experience is much better.

The second is timeliness, and the current nucleic acid program generally takes more than 6 hours to get results.

The timeliness of Dr. Zhang's plan only takes about half an hour, and there is even room for further improvement.

In addition, the accuracy is also high, the detection is convenient, and even the cost is not high.

All things considered, the results are clear.

After the internal laboratory verified that it was correct, the person in charge of the relevant pharmaceutical group began to contact Wuzhou Company, hoping to obtain the patent technology authorization.

Wu Zhou has full confidence in this technology, and the results given by the system are the best technology at the moment, and almost all aspects are the best. Even if the technology is announced now, it will take at least a few months for other related companies at home and abroad to follow up on the research and development of relevant technologies as soon as possible, but this is based on the premise of similar routes.

As for the technology patent, Wu Zhou has asked the company's lawyers to apply for patents in major markets around the world, and some related technical routes are also being studied by the company, and there has been some progress.

Moreover, patents can not only be applied for after the finished product is completely completed, but also can be divided into many small technologies.

What is certain is that it is very difficult to circumvent Wu Zhou's patent, and it is impossible to achieve results in the short term.

On May 19, the first Mi company hoped to cooperate and gave 10 million US dollars, hoping to obtain a global authorization, but Wu Zhou didn't even bother with it.

On May 21, three more companies were contacted, and Wu Zhou only contacted one of them, not to say how big this company is, but because this company has a good drug, Wu Zhou wants to get authorization

As the results of the internal verification of each company are released, more and more companies are contacting the Aiying Group.

On May 31, after some screening, Aiying Group invited the heads of 8 pharmaceutical companies in Huaxia to gather in Yuncheng.

In a silent conference room, an 8-meter-long wooden conference table is placed in the middle of the room, a white door that opens inward separates the room from the outside world, and a heavy white floor tile is laid on the floor, which makes the whole room look exceptionally bright through the sunlight of the window.

Wu Zhou sat in the main seat, surrounded by the company's technical staff, legal affairs, business negotiators, and other representatives of other related pharmaceutical companies, including Chinese and white, at this moment the two sides sat face to face, the atmosphere was tense and expectant.

"First of all, thank you very much for coming, as a newly established biomedical company, I would like to thank you for your attention and recognition of our company's related technologies." Wu Zhou said with a smile.

"Mr. Wu is polite, we are still the most powerful company in the biomedical field, the establishment of early or late does not mean that the company is strong or weak, Mr. Wu's large investment in the field of biomedicine, we are also very admired. In the future, I believe that there will be more cooperation opportunities with Mr. Wu's company. Someone said with a smile.

At this time, the project has not been discussed, of course, Wu Zhou is coaxed to say.

"However, Mr. Wu's achievements in the field of food, we have also heard of it before we came, and the food of Qiaofei's family is indeed very good, and I believe that the future Aiying medical-related products will definitely be able to make better products under the leadership of Mr. Wu and benefit countless patients."

After a bunch of flattering opening remarks, it's time for formal business negotiations.

"This technology, I believe that everyone who is doing it, before coming, must have already understood, this is the most advanced technology at the moment, there is no one." Wu Zhou said very confidently.

"Mr. Wu, your company is indeed leading in the application of this technology this time, but I think Mr. Wu must also know that CRISPR-related companies and teams, our country is the first to start researching, and we are the technology pioneers in this industry." A white man in a suit said to Wu Zhou seriously, the price was negotiated.

As long as the opponent feels that his thing is not rare enough, then of course the price will not be negotiable.

"Gunpowder was first invented by us Huaxia, but after a while, you used it better than us, didn't you." Wu Zhou responded with a smile.

Although this technology is as he said, it is more advanced in the United States, and it has even been applied to the clinical stage.

However, this time, Dr. Zhang's team has developed a new type of gene editing tool based on this technology, which has stronger accuracy, specificity and a wider range of applications.

Wu Zhou's confident gesture at the moment made the person in charge of a pharmaceutical company opposite, but the person in charge of a group of pharmaceutical companies on the opposite side looked at each other.

They couldn't tell if Wu Zhou was deliberately pretending, or if he really knew about the progress of foreign research.

But Wu Zhou didn't plan to chat with them anymore.

It's time to get down to business, these people are here to get a global license for this technology, and after they say their ideas, they can directly give a quote.

"Mr. Wu, our company invested 30 million US dollars, which is already the highest price I can get." But it was the head of the white pharmaceutical company.

Wu Zhou glanced at him. "That's a pity, it seems that we have no chance to cooperate with your company."

Others saw this, and the price went up sharply.

As more and more people made offers, and so did the number of competitors, the price began to rise.

100 million, $300 million, $500 million, and even $1.5 billion. It's like an auction market.

"It's too high, you're crazy." The person in charge of the pharmaceutical company who quoted 30 million couldn't help but accuse when he looked at the others around him.

Although this technology is the most advanced at the moment, at least at the moment, as long as someone updates the technology in the future, if the technology is better than the technology, then the patent licensing fee will be directly wasted.

Besides, masks look very serious now, but they may not be serious for how long in the future, and it is crazy to spend $1.5 billion on an uncertainty.

"Thank you for your recognition of our company's technology, the application process of new technologies will inevitably bring risks, such as being replaced by more advanced technology, our company will not do this kind of thing to hand over all the risks to partners."

"Although it is very important to make money, but for me, it doesn't matter if there is more or less, my original intention to enter the medical field is just to make good products that benefit ordinary people."

"It's a technology that detects masks, and now the severity of it, it's clear to everyone, and I hope that this technology can reach the general public more quickly and make a little contribution to stopping it from spreading further."

After Wu Zhou said a lot.

"Therefore, our company will not consider the buyout authorization for the time being, and what I hope is to share the license, with a proportion of 30%."

"Mr. Wu, we" Some people still want to fight for global channel authorization.

But Wu Zhou's attitude was resolute.

Wu Zhou's plan does make some people excited, after all, this can greatly reduce this risk.

"Mr. Wu, the proportion of 30% is too high, and we can only agree to 10% of the relevant technical cooperation patent fees at most, you see?"

"Of course there is no problem, 10% I can accept, but there are additional conditions, if this cooperation is established, then our company only needs to pay 10% for some of your company's products?"

After some back and forth, it was finally decided that it was 20%.

(End of chapter)